114 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
million, on an annual basis, of cash compensation related to salary, bonus, and benefits to affected employees. In February 2023, as part … a risk evaluation and mitigation strategy (“REMS”), to help ensure that the benefits of the drug outweigh the potential risks. REMS can include
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
, against contributions in kind or for the purpose of acquiring specific assets and granting specific benefits;
limiting or withdrawing shareholder’s pre … , pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the articles of association
F-3
EX-4.2
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
Mutilated, Destroyed, Lost or Stolen Securities
Section 2.08
Cancellation
Section 2.09
Benefits of Indenture
Section 2.10
Authenticating Agent
Section 2.11 … that the Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any
F-3
EX-4.1
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
, ou par l’émission d’actions nouvelles.
Compensation may be paid in the form of cash or in the form of other types of benefits. It can be paid … of the compensation.
Article 33: Prêts, crédits et prestations de prévoyance
Article 33: Loans, credits and retirement benefits
Sous réserve de l’article 34 para. 5
6-K
EX-99.3
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
to salary, bonus, and benefits to affected employees.
Debt restructuring: The Company restructured its debt owed to certain funds and accounts managed … statements regarding the status of ObsEva’s restructuring process, expected benefits from the sale of rights to ebopiprant to XOMA, ObsEva’s cash runway
6-K
EX-99.2
kdxudrfodyoyd
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
b6jlg jreakrazs6t
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
y83vonfsq
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
1cl9t7othpp
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
EX-99.2
z0eoeitc2d4t 6y
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
EX-99.1
3e1ipc7g69594ply81
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K/A
EX-99.1
c6o6a1icqezc5dh
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
EX-99.2
g1u98tcgx
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
6ikz4a4aris9l6mbxl
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
sumux4jlvn0s7f gic
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.1
mqdqur
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
aol1xpfn
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.2
vvkfvww0qfwyl7s ih
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.3
o6p4yl b66dw7lph36vz
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
dqb2xd1
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am